These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18391603)

  • 1. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
    Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
    Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
    Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
    Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
    Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
    Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xenovaccinotherapy for colorectal cancer.
    Seledtsov VI; Niza NA; Felde MA; Shishkov AA; Samarin DM; Seledtsova GV; Seledtsov DV
    Biomed Pharmacother; 2007; 61(2-3):125-30. PubMed ID: 17258887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
    Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
    J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
    J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
    Baldueva IA; Novik AV; Moiseenko VM; Nekhaeva TL; Danilova AB; Danilov AO; Protsenko SA; Petrova TIu; Uleĭskaia GI; Shchekina LA; Semenova AI; Mikhaĭlichenko TD; Teletaeva GM; Zhabina AS; Volkov NV; Komarov IuI
    Vopr Onkol; 2012; 58(2):212-21. PubMed ID: 22774527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
    Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
    Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
    Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study.
    Mordoh J; Kairiyama C; Bover L; Solarolo E
    Medicina (B Aires); 1997; 57(4):421-7. PubMed ID: 9674264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
    Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
    Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma.
    Hara W; Tran P; Li G; Su Z; Puataweepong P; Adler JR; Soltys SG; Chang SD; Gibbs IC
    Neurosurgery; 2009 Feb; 64(2 Suppl):A26-32. PubMed ID: 19165071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
    Atzpodien J; Morawek L; Fluck M; Reitz M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):901-5. PubMed ID: 19229537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma.
    Jha G; Miller JS; Curtsinger JM; Zhang Y; Mescher MF; Dudek AZ
    Am J Clin Oncol; 2014 Jun; 37(3):261-5. PubMed ID: 23241505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Necozione S; Fumagalli L; Rea S
    J Immunother; 2007; 30(4):448-54. PubMed ID: 17457219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.